IL96839A - Process for preparing a dried preparation of tumor factor 1 similar to insulin - Google Patents
Process for preparing a dried preparation of tumor factor 1 similar to insulinInfo
- Publication number
- IL96839A IL96839A IL9683990A IL9683990A IL96839A IL 96839 A IL96839 A IL 96839A IL 9683990 A IL9683990 A IL 9683990A IL 9683990 A IL9683990 A IL 9683990A IL 96839 A IL96839 A IL 96839A
- Authority
- IL
- Israel
- Prior art keywords
- acid
- dried composition
- preparing
- growth factor
- insulin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims abstract description 16
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title claims abstract description 7
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 title claims abstract 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims abstract description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims abstract description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000006408 oxalic acid Nutrition 0.000 claims abstract description 5
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims abstract description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940098779 methanesulfonic acid Drugs 0.000 claims abstract description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000006240 deamidation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- -1 dextran saccharides amino acids Chemical class 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OGNVQLDIPUXYDH-ZPKKHLQPSA-N (2R,3R,4S)-3-(2-methylpropanoylamino)-4-(4-phenyltriazol-1-yl)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid Chemical compound CC(C)C(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(O)=O)=C[C@@H]1N1N=NC(C=2C=CC=CC=2)=C1 OGNVQLDIPUXYDH-ZPKKHLQPSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000003068 pituitary dwarfism Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP88690 | 1990-01-05 | ||
| JP16236290 | 1990-06-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL96839A0 IL96839A0 (en) | 1991-09-16 |
| IL96839A true IL96839A (en) | 1995-03-30 |
Family
ID=26334000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9683990A IL96839A (en) | 1990-01-05 | 1990-12-31 | Process for preparing a dried preparation of tumor factor 1 similar to insulin |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5210074A (es) |
| EP (1) | EP0440989B1 (es) |
| JP (1) | JPH0818999B2 (es) |
| AT (1) | ATE120763T1 (es) |
| CA (1) | CA2033535A1 (es) |
| DE (1) | DE69018438T2 (es) |
| DK (1) | DK0440989T3 (es) |
| ES (1) | ES2070262T3 (es) |
| GR (1) | GR3015712T3 (es) |
| IL (1) | IL96839A (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW267102B (es) * | 1992-03-13 | 1996-01-01 | Ciba Geigy | |
| US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
| JP2001522813A (ja) * | 1997-11-07 | 2001-11-20 | カイロン コーポレイション | 新規のｉｇｆ−ｉ組成物およびその使用 |
| US7067485B2 (en) | 1997-11-07 | 2006-06-27 | Chiron Corporation | IGF-I composition and its use |
| US6284282B1 (en) | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
| WO1999055362A1 (en) * | 1998-04-29 | 1999-11-04 | Genentech, Inc. | Spray dried formulations of igf-i |
| ATE251466T1 (de) | 1999-04-08 | 2003-10-15 | Genentech Inc | Zusammensetzung auf basis gegensätzlich geladener polypeptide |
| ES2397712T3 (es) * | 2006-01-18 | 2013-03-08 | Qps, Llc | Composiciones farmacéuticas con estabilidad reforzada |
| WO2016103034A1 (en) * | 2014-12-23 | 2016-06-30 | Drug Discovery Laboratory As | Protein compositions and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4139611A (en) * | 1975-12-24 | 1979-02-13 | Helmut Mittenzweig | Organic peptide containing substance recovered from blood having insulin-like activity |
| US4371523A (en) * | 1980-12-29 | 1983-02-01 | The Regents Of The University Of California | Reducing the aggregation of insulin in solution |
| US4774091A (en) * | 1983-10-14 | 1988-09-27 | Sumitomo Pharmaceuticals Company, Ltd. | Long-term sustained-release preparation |
| US4985404A (en) * | 1984-10-04 | 1991-01-15 | Monsanto Company | Prolonged release of biologically active polypeptides |
| US4816568A (en) * | 1986-05-16 | 1989-03-28 | International Minerals & Chemical Corp. | Stabilization of growth hormones |
| NZ226170A (en) * | 1987-09-18 | 1990-07-26 | Ethicon Inc | Stable freeze-dried pharmaceutical composition containing epidermal growth factor |
-
1990
- 1990-12-25 JP JP2418399A patent/JPH0818999B2/ja not_active Expired - Lifetime
- 1990-12-26 US US07/633,984 patent/US5210074A/en not_active Expired - Lifetime
- 1990-12-29 ES ES90125816T patent/ES2070262T3/es not_active Expired - Lifetime
- 1990-12-29 DK DK90125816.0T patent/DK0440989T3/da active
- 1990-12-29 EP EP90125816A patent/EP0440989B1/en not_active Expired - Lifetime
- 1990-12-29 AT AT90125816T patent/ATE120763T1/de not_active IP Right Cessation
- 1990-12-29 DE DE69018438T patent/DE69018438T2/de not_active Expired - Lifetime
- 1990-12-31 IL IL9683990A patent/IL96839A/en not_active IP Right Cessation
-
1991
- 1991-01-03 CA CA002033535A patent/CA2033535A1/en not_active Abandoned
-
1995
- 1995-04-06 GR GR950400768T patent/GR3015712T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0440989B1 (en) | 1995-04-05 |
| JPH04208228A (ja) | 1992-07-29 |
| IL96839A0 (en) | 1991-09-16 |
| ES2070262T3 (es) | 1995-06-01 |
| US5210074A (en) | 1993-05-11 |
| ATE120763T1 (de) | 1995-04-15 |
| DE69018438D1 (de) | 1995-05-11 |
| JPH0818999B2 (ja) | 1996-02-28 |
| DE69018438T2 (de) | 1995-08-24 |
| CA2033535A1 (en) | 1991-07-06 |
| DK0440989T3 (da) | 1995-05-01 |
| GR3015712T3 (en) | 1995-07-31 |
| EP0440989A1 (en) | 1991-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hudson et al. | Studies on the native and reduced alkylated renal glomerular basement membrane: Solubility, subunit size, and reaction with cyanogen bromide | |
| EP0409870B1 (en) | Human growth hormone formulation | |
| Yonemasu et al. | Chemical studies on Clq; a modulator of immunoglobulin biology | |
| EP0128849B1 (en) | Purified transforming growth factor-beta derived from human platelets and placentas | |
| Kang et al. | Amino acid sequence of cyanogen bromide peptides from the amino-terminal region of chick skin collagen | |
| Scaramuzza et al. | A new site-specific monoPEGylated filgrastim derivative prepared by enzymatic conjugation: production and physicochemical characterization | |
| CN1181974A (zh) | 低糖分、稳定的、不含白蛋的一种重组体凝血因子制剂 | |
| Carsten et al. | Actin: a comparative study | |
| JP2003503464A (ja) | ポリエチレングリコールを有するエリスロポエチン接合体 | |
| JPS60228422A (ja) | 安定化された生理活性物質製剤 | |
| Dixon et al. | The isolation and structure of α-melanocyte-stimulating hormone from horse pituitaries | |
| EP0804223B1 (en) | Hgh containing pharmaceutical compositions | |
| JPH06228199A (ja) | 血液脳関門通過可能なペプチド結合体 | |
| IL96839A (en) | Process for preparing a dried preparation of tumor factor 1 similar to insulin | |
| MXPA05005178A (es) | Isomeros posicionales del interferon alfa 2a (ifn) pegilado con una porcion de polietilenglicol grande (peg). | |
| Hjorth et al. | Purification and identification of high molecular weight products formed during storage of neutral formulation of human insulin | |
| EP2982680A1 (en) | Protamine peptidomimetic, and pharmaceutically acceptable salts and use thereof | |
| Bristow et al. | The Second International Standard for somatropin (recombinant DNA-derived human growth hormone): preparation and calibration in an international collaborative study | |
| KR101104574B1 (ko) | 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도 | |
| Santana et al. | Molecular characterization of recombinant human interferon alpha-2b produced in Cuba | |
| Qin et al. | Isoform separation and structural identification of mono-PEGylated recombinant human growth hormone (PEG-rhGH) with pH gradient chromatography | |
| US5576301A (en) | Low molecular growth potentiating peptides | |
| JPS5950315B2 (ja) | ポリペプチドの製法 | |
| WO2015071368A1 (en) | Long-acting insulin glargine analogue | |
| CN117017928B (zh) | 一种水蛭素或水蛭素类似物环肽的冻干粉及制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| HC | Change of name of proprietor(s) | ||
| KB | Patent renewed | ||
| EXP | Patent expired |